Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

AGLE | Aeglea BioTherapeutics Inc

Index	-	P/E	-	EPS (ttm)	-73.71	Insider Own	9.33%	Shs Outstand	4.05M	Perf Week	3.29%
Market Cap	49.61M	Forward P/E	-	EPS next Y	-6.78	Insider Trans	0.00%	Shs Float	3.67M	Perf Month	-13.73%
Income	-272.56M	PEG	-	EPS next Q	-0.84	Inst Own	70.28%	Short Float / Ratio	3.30% / 1.94	Perf Quarter	8.77%
Sales	1.23M	P/S	40.34	EPS this Y	-166.67%	Inst Trans	-	Short Interest	0.12M	Perf Half Y	68.62%
Book/sh	-64.00	P/B	-	EPS next Y	89.73%	ROA	-155.64%	Target Price	15.62	Perf Year	2.92%
Cash/sh	58.11	P/C	0.21	EPS next 5Y	-	ROE	-163.26%	52W Range	2.66 - 39.00	Perf YTD	8.91%
Dividend	-	P/FCF	-	EPS past 5Y	11.19%	ROI	-	52W High	-68.59%	Beta	2.55
Dividend %	-	Quick Ratio	1.03	Sales past 5Y	-42.57%	Gross Margin	-59.28%	52W Low	360.53%	ATR	1.48
Employees	69	Current Ratio	1.03	Sales Q/Q	10.08%	Oper. Margin	-6961.16%	RSI (14)	46.89	Volatility	10.44% 13.48%
Optionable	No	Debt/Eq	-	EPS Q/Q	-736.54%	Profit Margin	-22195.36%	Rel Volume	0.16	Prev Close	11.46
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 11 BMO	Payout	-	Avg Volume	62.56K	Price	12.25
Recom	2.00	SMA20	-6.91%	SMA50	-7.07%	SMA200	27.22%	Volume	10,132	Change	6.89%

Date	Action	Analyst	Rating Change	Price Target Change
May-04-20	Initiated	Piper Sandler	Overweight	$12
Mar-21-19	Initiated	JP Morgan	Overweight	$14
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform	$37
Mar-14-18	Reiterated	Needham	Buy	$8 → $12

Sep-14-23 05:03PM	Aeglea BioTherapeutics to Participate in Upcoming September Conference (PR Newswire) -6.63%
Sep-07-23 08:40AM	Aeglea BioTherapeutics Announces Reverse Stock Split (PR Newswire)
Sep-05-23 07:00AM	Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones (PR Newswire)
Aug-11-23 07:07AM	Aeglea: Q2 Earnings Snapshot (AP Finance)
07:00AM	Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
07:00AM	Loading…
Jul-27-23 07:00AM	Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma (PR Newswire)
Jun-23-23 04:30PM	Aeglea BioTherapeutics Announces Grant of Inducement Awards (PR Newswire) -12.30%
10:31AM	Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics (Zacks)
Jun-22-23 10:59AM	Aeglea BioTherapeutics Stock Surges Over 400% Today - What's Going On (Benzinga) +328.67%
08:17AM	Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics (PR Newswire)
May-13-23 08:03AM	Aeglea BioTherapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-11-23 08:15AM	Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Aeglea: Q1 Earnings Snapshot (AP Finance)
07:01AM	Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-13-23 09:44AM	Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails (Zacks) -7.37%
07:00AM	Loading…
Apr-12-23 07:00AM	Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives (PR Newswire) -26.21%
Mar-17-23 05:30PM	Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.35%
Mar-02-23 10:15AM	Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates (PR Newswire)
Feb-12-23 07:40AM	Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) insiders placed bullish bets worth US$695k in the last 12 months (Simply Wall St.)
Jan-06-23 07:01AM	Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency (PR Newswire)
Jan-02-23 07:29AM	Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely (Simply Wall St.)
Dec-14-22 12:00PM	Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-02-22 04:05PM	Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +18.17%
Nov-30-22 10:38AM	Aeglea Nosedives After Clinical Update On Investigational Candidate For Rare Metabolism Disease (Benzinga) -65.98%
07:01AM	Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer (PR Newswire)
Nov-15-22 04:25PM	Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer (PR Newswire) -5.88%
Nov-03-22 08:35AM	Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.56%
07:01AM	Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates (PR Newswire)
Oct-21-22 12:27PM	Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers (Zacks) +6.02%
12:06PM	Loading…
12:06PM	AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition (Zacks)
Oct-19-22 04:05PM	Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment (PR Newswire)
Oct-17-22 11:57AM	NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce (Zacks)
Oct-04-22 11:05AM	FDA Puts Partial Hold On Aeglea's Rare Disorder Trial In Pediatric Patients (Benzinga)
07:01AM	Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program (PR Newswire)
Aug-29-22 04:05PM	Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 (PR Newswire) +16.74%
Aug-27-22 09:18AM	Trade Alert: Marcio De'Souza At Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), Has Just Spent US$50k Buying A Small Number of Shares (Simply Wall St.)
Aug-25-22 11:52AM	Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down (Zacks)
Aug-24-22 12:40PM	Aeglea Bio Feels FDA Refusal Pinch, Cuts Workforce, Shifts Pipeline Focus (Benzinga) -19.87%
08:01AM	Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring (PR Newswire)
Aug-22-22 12:28PM	Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment (Zacks) -17.15%
Aug-20-22 10:49AM	Even after rising 85% this past week, Aeglea BioTherapeutics (NASDAQ:AGLE) shareholders are still down 88% over the past three years (Simply Wall St.)
Aug-19-22 06:26AM	Read Why Aeglea BioTherapeutics Shares Are Skyrocketing Today? (Benzinga) +80.23%
Aug-18-22 04:05PM	Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency (PR Newswire)
Aug-04-22 08:35AM	Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.41%
07:01AM	Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates (PR Newswire)
Jul-24-22 10:41AM	Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely (Simply Wall St.)
Jul-08-22 11:14AM	Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why (Zacks)
Jul-07-22 11:22AM	Adverum (ADVM) Completes IND Amendment for Gene Therapy Study (Zacks)
Jul-04-22 11:49AM	Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU (Zacks)
Jun-29-22 12:34PM	Graybug (GRAY) to Review Strategic Alternatives, Stock Up (Zacks) -5.22%
Jun-28-22 11:52AM	Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD (Zacks) -6.86%
10:23AM	Kezar (KZR) Doubles on Promising Kidney Disorder Study Data (Zacks)
Jun-13-22 12:01PM	Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development (Zacks)
Jun-09-22 09:56AM	Having purchased US$1.8m worth of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) stock, the recent 53% pullback is not what insiders may have expected (Simply Wall St.)
Jun-03-22 10:49AM	Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug (Zacks) -14.51%
Jun-02-22 03:26PM	Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug (Zacks) -51.33%
03:20PM	Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals (Zacks)
12:09PM	Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy (Zacks)
11:24AM	Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug (Zacks)
08:59AM	Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency (PR Newswire)
Jun-01-22 02:25PM	BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug (Zacks) -5.06%
02:22PM	FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug (Zacks)
May-31-22 11:26AM	GSK to Boost Vaccine Portfolio With Affinivax Acquisition (Zacks)
May-26-22 11:18AM	Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe (Zacks)
May-25-22 12:07PM	INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study (Zacks) +9.49%
May-23-22 11:46AM	AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate (Zacks)
11:33AM	Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata (Zacks)
May-20-22 09:50AM	Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase (Zacks)
May-18-22 11:47AM	Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate (Zacks)
11:03AM	Horizon (HZNP) Begins Enrollment in Alopecia Areata Study (Zacks)
May-17-22 11:31AM	Seagen's (SGEN) Stock Up on CEO's Resignation Announcement (Zacks) +7.69%
May-13-22 10:30AM	Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia (Zacks) +5.34%
May-11-22 09:47AM	Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs (Zacks) -8.16%
May-05-22 09:28AM	Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market (PR Newswire)
07:45AM	Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
06:30AM	Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates (PR Newswire)
Apr-13-22 12:42PM	Aeglea (AGLE) Submits BLA for a Rare Disease Drug to the FDA (Zacks) -6.28%
Apr-12-22 08:10AM	Aeglea's stock rises after asking the FDA to approve therapy for rare disorder (MarketWatch) -8.23%
06:01AM	Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency (PR Newswire)
Apr-11-22 04:30PM	Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD (PR Newswire) -6.54%
Apr-06-22 07:59AM	Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022 (PR Newswire)
Mar-29-22 07:59AM	Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual Meeting (PR Newswire)
Mar-08-22 08:35AM	Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-10-22 09:29AM	Aeglea BioTherapeutics Withdraws Public Offering (PR Newswire) -6.22%
Feb-09-22 04:01PM	Aeglea BioTherapeutics Announces Proposed Public Offering (PR Newswire)
Feb-02-22 04:39AM	We're Hopeful That Aeglea BioTherapeutics (NASDAQ:AGLE) Will Use Its Cash Wisely (Simply Wall St.)
Jan-25-22 08:01AM	Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 Deficiency (PR Newswire)
Jan-05-22 07:01AM	Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022 (PR Newswire)
Dec-17-21 06:14AM	3 Biotech Stocks That Sank: Are Any a Bad-News Buy? (Motley Fool) +14.41%
Dec-14-21 09:15AM	Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $198,982 of Shares (GuruFocus.com)
Dec-12-21 06:18AM	What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition (Simply Wall St.)
Dec-06-21 01:01PM	Why Aeglea BioTherapeutics Stock Is Way Down Today (Motley Fool) -36.50%
07:18AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:30AM	Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency (PR Newswire)
Dec-05-21 06:00PM	Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency (PR Newswire)
Nov-16-21 07:01AM	Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors (PR Newswire)
Nov-04-21 08:55AM	Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:01AM	Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights (PR Newswire)
06:59AM	Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics (PR Newswire)

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Waltham, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGLE | Aeglea BioTherapeutics Inc

Upgrade your FINVIZ experience